New Frontiers in ADC Analysis: Exploring Advances in Chromatography, Electrophoresis & Mass Spectrometry

• Defining CQAs of antibody and bispecific Drug Substance intermediates and ADC Drug Substances and Drug Products
• Exploring the role of cutting-edge analytical strategies based on the use of LC, CE, and MS, either as standalone techniques or in combination
• Evaluating use of tailored analytical methods for comprehensive ADC characterisation and early developability assessment with relevant benchmarks

Speakers:

Alain Beck

Senior Director, Biologics CMC Developability

Pierre Fabre